LENSAR (LNSR) Q2 2026 earnings review
Post-Merger Rebound Arrives Faster Than Expected
LENSAR violently broke its Q1 'merger limbo' slump, posting 18% YoY revenue growth and record profitability. The termination of the Alcon deal had severely stalled system sales in early 2026, but Q2 saw system placements recover to 10 ALLY units, up from 7 in Q1. More impressively, the underlying procedure volume surged 13% to a record 58,682, driving recurring revenue to 83% of the total mix. While management previously cautioned that the recovery would take multiple quarters, the massive $3.6M Adjusted EBITDA print suggests the operating leverage of the ALLY installed base is already shining through.
🐂 Bull Case
Procedure revenue jumped 23% YoY to $10.2M. With an installed base of 445 systems generating continuous high-margin lease, service, and procedure fees, LENSAR is highly insulated from capital spending volatility.
Adjusted EBITDA swung from negative $0.3M in 26Q1 to positive $3.6M this quarter, proving that once M&A-related distractions and costs are removed, the core business generates significant cash.
🐻 Bear Case
Despite management celebrating a 30% YoY increase in the overall ALLY installed base, the 10 placements this quarter represents a massive deceleration compared to the 18 systems placed in 25Q2. The sales channel is still impaired.
The reported $3.5M Net Income heavily benefited from a $1.1M macro-driven tariff refund and a $1.2M non-cash change in warrant liabilities. Underlying operating margin is thinner than headline numbers suggest.
⚖️ Verdict: 🟢
Bullish. The speed at which LENSAR shook off the failed Alcon merger and returned to robust top-line growth and record procedure volumes is highly encouraging. The recurring revenue engine is structurally sound, giving management breathing room to rebuild the capital sales pipeline.
Key Themes
Record Utilization Driving High-Margin Mix
Procedure volume accelerated to 58,682 (+13% YoY and +8% QoQ). This indicates that surgeons actively utilizing the ALLY System and its proprietary Streamline software are heavily adopting the technology for premium cataract procedures. Because of this high utilization, total recurring revenue reached $13.7M, comprising a massive 83% of total revenue. This recurring engine provides exceptional visibility and downside protection.
System Placements Still Rebuilding
Management framed Q2 as a return to momentum, highlighting 10 ALLY placements (up from 7 in Q1). However, historical data contradicts the celebration: LENSAR placed 18 ALLY systems in both 25Q2 and 25Q3, and 15 in 25Q4. Placing only 10 systems shows that the international distributor network (OUS) and domestic capital equipment sales channels are still deeply damaged from the Alcon 'limbo' period and will require heavy lifting to fully repair.
OpEx Reset Accelerates Profitability
Selling, general and administrative (SG&A) expenses plunged to $6.1M in Q2, down drastically from $11.7M a year ago. While last year's number was inflated by $4.2M in M&A costs, the structural cost base remains incredibly lean. This disciplined expense management directly fueled the record $3.6M Adjusted EBITDA.
Macro Tailwinds: Tariff Refunds
Net income and gross margins were temporarily juiced by a $1.1 million tariff refund. Management successfully reclaimed these costs, but investors must strip this out to accurately assess go-forward operating margins, as this is a non-recurring macro benefit.
Pending OpEx Ramp
In the prior quarter, the outgoing CFO explicitly warned that SG&A would need to increase organically from current run rates to aggressively rebuild the service and sales teams depleted during the merger process. The lean Q2 OpEx profile may not be sustainable as LENSAR invests to revitalize the system sales channel.
Other KPIs
Stable sequentially compared to $13.5M at the end of Q1. The company successfully halted its cash burn this quarter, driven by the strong operating leverage of the recurring revenue model and the one-time tariff refund. This alleviates near-term liquidity concerns while they rebuild the sales pipeline.
Accelerating significantly from roughly 47.5% in Q1. Calculated as total revenue ($16.5M) minus cost of revenue ($6.7M). A larger mix of highly profitable procedure revenue, paired with the $1.1M tariff cost clawback, drove this outsized profitability metric.
Guidance
Stable. As of June 30, the company had 13 ALLY systems pending installation. This provides baseline visibility for Q3 capital revenue, but shows that the order book has not dramatically expanded compared to historical backlog levels (which stood at 18 in mid-2025).
Key Questions
Quality of Placements
Of the 10 ALLY systems placed this quarter, what was the geographic breakdown (US vs. OUS), and how is the international distributor network responding to the re-engagement efforts post-Alcon?
Sustainable OpEx Profile
SG&A was exceptionally lean this quarter at $6.1M. How much of the planned 'judicious hiring' in sales and service is already reflected in this number, and what is the expected SG&A run rate for the second half of the year?
Tariff Dynamics
You secured a $1.1 million tariff refund in Q2. Are there any outstanding tariff refunds still pending, and how should we model standard cost of goods sold going forward absent these refunds?
System Upgrades vs Conquests
How much of the system placement growth is driven by competitive displacements (e.g., Alcon LensX users) versus upgrading your existing legacy LENSAR installed base?